RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
14,34Â $US
arrow_downward
-1,10%(-0,16) 1J
28 sept., 14:33:06 UTC−4 · USD
search
Tous les symboles
1J
5J
1M
6M
Depuis début année
1AN
5ANS
MAX
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour RARE...
Ouverture
14,33Â $US
Élevé
14,45Â $US
Faible
14,11Â $US
Cap. boursière
1,41Â Md
Vol. moyen
5,32Â M
Volume
1,90Â M
+Â haut sur 1Â an
39,89Â $US
+Â bas sur 1Â an
12,73Â $US
BPA
-5,84Â $US
Bêta
0,32
Actions en circulation
98,59Â M
Nombre d'employés
1Â k
Ouverture
14,33Â $US
Élevé
14,45Â $US
Faible
14,11Â $US
Cap. boursière
1,41Â Md
Vol. moyen
5,32Â M
Volume
1,90Â M
+Â haut sur 1Â an
39,89Â $US
+Â bas sur 1Â an
12,73Â $US
BPA
-5,84Â $US
Bêta
0,32
Actions en circulation
98,59Â M
Nombre d'employés
1Â k
Articles
Sources : Web et partenaires du secteur de l'information
MarketBeat
·
il y a 2 jours
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analysts
Investing.com
·
il y a 3 jours
H.C. Wainwright reiterates Ultragenyx stock rating on FDA approval
Profil
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
À propos de Ultragenyx Pharmaceutical Inc
PDGEmil Kakkis
Employés1,37 k
Date de création2010
Siège socialNovato, Californie, États-Unis
Secteur-
Site Webultragenyx.com